Literature DB >> 25899659

Post-PCI Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation.

Mahesh V Madhavan1, Ajay J Kirtane.   

Abstract

The number of patients who undergo percutaneous coronary intervention (PCI) and additionally require chronic anticoagulation for a variety of indications is not insignificant. The choice of antithrombotic therapy after PCI in patients with chronic indications for anticoagulation therapy remains a challenge for interventional cardiologists, as the risk of bleeding must be adequately weighed against the benefit of preventing future ischemic events. While these clinical scenarios are encountered in approximately 10 % of patients undergoing PCI, current practice guidelines do not sufficiently guide physicians as to how to best treat these PCI patients requiring chronic anticoagulation. Notwithstanding the clinical difficulties of treating such patients, there are several recent studies and analyses that have assessed optimal antithrombotic strategies in the PCI population, and there are several others that are currently underway. This review evaluates the currently available data and clinical scenarios commonly encountered by treating physicians.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25899659     DOI: 10.1007/s11886-015-0598-4

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  60 in total

1.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

Authors:  Fausto Feres; Ricardo A Costa; Alexandre Abizaid; Martin B Leon; J Antônio Marin-Neto; Roberto V Botelho; Spencer B King; Manuela Negoita; Minglei Liu; J Eduardo T de Paula; José A Mangione; George X Meireles; Hélio J Castello; Eduardo L Nicolela; Marco A Perin; Fernando S Devito; André Labrunie; Décio Salvadori; Marcos Gusmão; Rodolfo Staico; J Ribamar Costa; Juliana P de Castro; Andrea S Abizaid; Deepak L Bhatt
Journal:  JAMA       Date:  2013-12-18       Impact factor: 56.272

Review 3.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

4.  Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention: insight into the RISK-PCI trial.

Authors:  Igor Mrdovic; Lidija Savic; Gordana Krljanac; Jovan Perunicic; Milika Asanin; Ratko Lasica; Nebojsa Antonijevic; Nikola Kocev; Jelena Marinkovic; Zorana Vasiljevic; Miodrag Ostojic
Journal:  Coron Artery Dis       Date:  2012-01       Impact factor: 1.439

5.  Postprocedural anticoagulation for specific therapeutic indications after revascularization for ST-segment elevation myocardial infarction (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial).

Authors:  Mahesh V Madhavan; Philippe Généreux; Ajay J Kirtane; Ke Xu; Bernhard Witzenbichler; Roxana Mehran; Gregg W Stone
Journal:  Am J Cardiol       Date:  2014-08-11       Impact factor: 2.778

6.  One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry.

Authors:  Andrea Rubboli; Axel Schlitt; Tuomas Kiviniemi; Fausto Biancari; Pasi P Karjalainen; Josè Valencia; Mika Laine; Paulus Kirchhof; Matti Niemelä; Saila Vikman; Gregory Y H Lip; K E Juhani Airaksinen
Journal:  Clin Cardiol       Date:  2014-01-30       Impact factor: 2.882

7.  Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.

Authors:  Jonas Oldgren; Andrzej Budaj; Christopher B Granger; Yasser Khder; Juliet Roberts; Agneta Siegbahn; Jan G P Tijssen; Frans Van de Werf; Lars Wallentin
Journal:  Eur Heart J       Date:  2011-05-07       Impact factor: 29.983

8.  Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.

Authors:  Nikolaus Sarafoff; Amadea Martischnig; Jill Wealer; Katharina Mayer; Julinda Mehilli; Dirk Sibbing; Adnan Kastrati
Journal:  J Am Coll Cardiol       Date:  2013-03-21       Impact factor: 24.094

9.  Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.

Authors:  Roxana Mehran; Alexandra J Lansky; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; S Chiu Wong; Eugenia Nikolsky; Louise Gambone; Lynn Vandertie; Helen Parise; George D Dangas; Gregg W Stone
Journal:  Lancet       Date:  2009-08-28       Impact factor: 79.321

10.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Authors:  M B Leon; D S Baim; J J Popma; P C Gordon; D E Cutlip; K K Ho; A Giambartolomei; D J Diver; D M Lasorda; D O Williams; S J Pocock; R E Kuntz
Journal:  N Engl J Med       Date:  1998-12-03       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.